Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call
August 03, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial...
Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 18, 2020 10:31 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614...
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock
June 15, 2020 22:35 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public...
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
June 15, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market...
Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile
June 06, 2020 03:01 ET
|
Celldex Therapeutics, Inc.
--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE...
Celldex Provides Corporate Update and Reports First Quarter 2020 Results
May 06, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite the...
Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020
May 06, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster...
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
March 26, 2020 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019. ...
Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program
March 03, 2020 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement...
Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159
November 18, 2019 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a...